NCT06829329

Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)

A Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With CHB

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 105 (actual)
• Sponsor: Ausper Biopharma Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study is to evaluate the efficacy and safety of AHB-137 in CHB participants. The total duration of the study, including screening phase, treatment phase and follow-up phase.

Conditions

• Chronic Hepatitis B

Interventions

Type	Name	Description
DRUG	AHB-137	AHB-137 will be administered .
DRUG	NAs	NAs will be administered.
DRUG	Placebo	Placebo will be administered .

Timeline

• Start date: 2024-12-13
• Primary completion: 2025-10-21
• Completion: 2025-11-01
• First posted: 2025-02-17
• Last updated: 2025-09-24

Locations

4 sites across 1 country: China